LUCD Share Price Performance
US$1.30
0.10 (8.33%)
74.0% undervalued intrinsic discount
US$5.00
Fair Value
Price US$1.30
InvestingNurse US$5.00
AnalystHighTarget US$9.00
AnalystLowTarget US$2.50
Fair ValueUS$5.00
Share Pricen/a
Lucid Diagnostics Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
LUCD Community Narratives
IN
Fair Value US$5 74.0% undervalued intrinsic discount
Poised for success
1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$9 85.6% undervalued intrinsic discount
Aging Demographics And Medicare Coverage Will Spur Early Detection
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$2.5 48.0% undervalued intrinsic discount
Medicare Coverage Delays Will Exacerbate Cash Burn Yet Yield Recovery
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Read more
74
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
IN
US$5
74.0% undervalued intrinsic discount
Fair Value
Profit Margin
13.44%
Future PE
24.75x
Price in 2031
US$7.33
Aging Demographics And Medicare Coverage Will Spur Early Detection
Key Takeaways Accelerating insurance coverage, including Medicare and private payers, signals a tipping point for rapid test adoption and transformative revenue and margin growth. Scalable health system integration and operational infrastructure position Lucid to leverage rising demand for preventive diagnostics, supporting sustained, profitable expansion.Read more
23
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$9
85.6% undervalued intrinsic discount
Fair Value
Profit Margin
12.7%
Future PE
602.4x
Price in 2029
US$11.32
Medicare Coverage Delays Will Exacerbate Cash Burn Yet Yield Recovery
Key Takeaways Lucid faces significant risks from slow clinician adoption, uncertain reimbursement, and evolving regulatory landscapes, potentially delaying revenue growth and path to profitability. Ongoing high cash burn and potential for increased dilution or debt could constrain long-term financial stability, despite a favorable market outlook for early cancer detection.Read more
30
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$2.5
48.0% undervalued intrinsic discount
Fair Value
Profit Margin
13.36%
Future PE
126.11x
Price in 2029
US$3.13
Medicare Coverage And Health Partnerships Will Unlock Future Potential
Key Takeaways Expanding insurance coverage and Medicare access are poised to drive significant revenue growth and improve payment predictability. Strategic health system partnerships and greater medical guideline support position the company for scalable adoption and long-term market expansion.Read more
39
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$3.63
64.1% undervalued intrinsic discount
Fair Value
Profit Margin
12.49%
Future PE
131.12x
Price in 2028
US$2.52
Trending Discussion
Recently Updated Narratives
IN
Poised for success
Fair Value: US$5 74.0% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LUCD: Revised Outlook Suggests VA Contract Will Support Future Repricing
Fair Value: US$9 85.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LUCD: VA Contract Will Expand Screening Access And Support Future Upside
Fair Value: US$2.5 48.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lucid Diagnostics Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.41
- -41.73%
- -1,499.55%
- 219.5%
About LUCD
- Founded
- 2018
- Employees
- 82
- CEO
- WebsiteView website
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
